

FOI 73-2022 – Number of Commercial Clinical Trials taking place in CCC 2021

Total: 138 (Open to recruitment: 29, Closed to Recruitment – In follow-up: 109)

Open to Recruitment

Project Acronym	Project Full title	Project phase	Project type	Principal Investigator	Disease Group	Project site date open to recruitment
ACIT-1	A Phase I clinical study to determine the optimal dose for the safe immune restoration and immune response of allogeneic cell immunotherapy (ACIT-1) in adult cancer patients	Phase I	Commercial non-portfolio	Palmer, Prof Daniel	Upper GI	27/03/2017
AMG 20150136	An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices	Phase IV	Commercial portfolio	Toth, Dr Arpad (Gabe)	Haematological	16/03/2018
ANNAR (EDDA)	Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations	Not Applicable	Commercial portfolio	Syndikus, Dr Isabel	Bladder	17/12/2020
ASSURE	A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia	Phase III	Commercial portfolio	Pettitt, Prof Andy	Haematological	19/02/2021
BET Inhibitor 0610-02 (MANIFEST)	A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Haematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)	Phase II	Commercial portfolio	Butt, Dr Nauman	Haematological	20/05/2019
CA209-73L	A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)	Phase III	Commercial portfolio	Haridass, Dr Anoop	Lung	04/02/2020
CARINA	A Multicentre, Retrospective, Non-Interventional Review Of Electronic Prescribing Records Of Any Second-Line (2l) Patients And Chart Notes Of 2l Cabozantinib Patients, Investigating The Treatment Sequence Pathway Following A First-Line, Immuno-Oncology Checkpoint Inhibitor (1l Io) Containing Combination Therapy In Patients With Advanced Renal Cell Carcinoma (Arcc) (Carina)	Not Applicable	Commercial portfolio	Chow, Dr Shien	A Select Disease Group Type	18/01/2022
FLAURA-2	A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA-2)	Phase III	Commercial portfolio	Escriu, Dr Carlos	Lung	07/10/2020
IMC-103C-101 - MAGE Trial	A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer	Phase I/II	Commercial portfolio	Sacco , Dr Joseph	A Select Disease Group Type	21/02/2022
IMMbrane 251	A Phase Iii, Open-Label, Randomized Study Of Atezolizumab With Lenvatinib Or Sorafenib Versus Lenvatinib Or Sorafenib Alone In Hepatocellular Carcinoma Previously Treated With Atezolizumab And Bevacizumab	Phase III	Commercial portfolio	Palmer, Prof Daniel	Sarcoma	28/02/2022
irAEs in patients with melanoma/RCC receiving nivolumab/ipilimumab	Investigating the management and outcomes of patients who experience immune-related adverse events following treatment with immune checkpoint inhibitor therapy	Not Applicable	Commercial portfolio	Olsson-Brown, Anna		02/02/2022
KEYNOTE 867	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)	Phase III	Commercial portfolio	Haridass, Dr Anoop	Lung	05/02/2021
KEYNOTE 937	Adjuvant Therapy with Pembrolizumab Versus Placebo in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation	Phase III	Commercial portfolio	Palmer, Prof Daniel	Upper GI	13/07/2020

LI8998 Abemaciclib MBC Chart Review Study	Observational Study on HR+/HER2- Locally Advanced / Metastatic Breast Cancer Patients treated with Abemaciclib in UK & Germany	Not Applicable	Commercial portfolio	Palmieri , Prof Carlo	A Select Disease Group Type	25/11/2021
M19-388	An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial	Phase III	Commercial portfolio	Pettitt, Prof Andy	Haematological	22/10/2020
ME-401 in Subjects with Follicular Lymphoma	A Multicenter, Open-Label, Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects with Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies – The TIDAL Study	Phase II	Commercial portfolio	Pettitt, Prof Andy	Haematological	24/12/2019
MO40653 IMREAL	A non-interventional, multicenter, multiple cohort study investigating the outcomes and safety of atezolizumab under real-world conditions in patients treated in routine clinical practice	Not Applicable	Commercial portfolio	Syndikus, Dr Isabel	A Select Disease Group Type	20/03/2019
MOAT Study	A multicentre, open-label, non-randomized, phase Ib, neoadjuvant study of intravenous dosing of NG-641, an oncolytic adenoviral vector expressing a fibroblast activation protein-directed bi-specific T-cell activator antibody fragment (FAP-Tac) and an immune enhancer module (CXCL9/CXCL10/interferon alpha2), as monotherapy or in combination with pembrolizumab in patients with surgically resectable squamous cell carcinoma of the head and neck (Mode Of Action Transgene study- MOAT)	Phase I	Commercial portfolio	Ottensmeier, Prof Christian	Head & Neck	04/11/2021
NeoADAURA	A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)	Phase III	Commercial portfolio	Escriu, Dr Carlos	Lung	15/11/2021
OVAL-1	Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK OVAL-1: A pan-European non-interventional, retrospective observational cohort study of patients with BRCA mutated advanced (FIGO stage III-IV) ovarian cancer treated with olaparib tablets in the first-line maintenance setting	Not Applicable	Commercial portfolio	Lord , Dr Rosie	Gynaecological	15/02/2021
PFIZER B1761031	A single arm, open-label, phase 4 study evaluating qt interval, pharmacokinetics, and safety of gemtuzumab ozogamicin (mylotarg™) as a single-agent regimen in patients with relapsed or refractory cd33-positive acute myeloid leukemia	Phase IV	Commercial portfolio	Toth, Dr Arpad (Gabe)	Haematological	13/12/2019
REPLIMUNE	An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors	Phase I/II	Commercial portfolio	Sacco , Dr Joseph	Melanoma	24/10/2018
REPLIMUNE 2	An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors	Phase I	Commercial portfolio	Sacco , Dr Joseph	Melanoma	17/10/2019
SKYSCRAPER-07	A Phase Iii, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab With Or Without Tiragolumab (Anti-Tigit Antibody) In Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma	Phase III	Commercial portfolio	Eswar, Dr Chinnamani		12/11/2021
SMARTPLUS-301 (TrilynX)	SMARTPLUS-301: A randomized, double-blind placebo-controlled, phase III study of Debio 1143 in combination with standard platinum-based concomitant fractionation chemoradiation therapy (CRT) in high-risk patients with inoperable locally advanced squamous cell carcinoma of the head and neck.		Commercial portfolio	,	Head & Neck	07/02/2022
TAK-788	A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	Phase III	Commercial portfolio	Escriu, Dr Carlos	Lung	22/02/2022
The Proof Trial	A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial	Phase III	Commercial portfolio	Palmer, Prof Daniel	Upper GI	21/01/2021
TNE NDMM PASS	A prospective non-interventional post-authorization safety study (PASS) of lenalidomide in previously untreated adult multiple myeloma patients who are not eligible for transplant (“transplant noneligible” [TNE]) (“Revlimid® TNE NDMM PASS”)		Commercial portfolio	Hawkins, Dr Stephen	Haematological	19/06/2020
VERASTEM 229	A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non-Hodgkin Lymphoma (iNHL)	Phase II	Commercial portfolio	Pettitt, Prof Andy	Haematological	27/11/2020

Closed to Recruitment – In follow-up

Project Acronym	Project Full title	Project phase	Project type	Principal Investigator	Disease Group	Project site date open to recruitment
RAGNAR - 42756493CAN2002	A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations	Phase II	Commercial portfolio	Palmer, Prof Daniel	A Select Disease Group Type	21/02/2020
VIABLE (SOTIO)	VIABLE (DCVAC/PCa)	Phase III	Commercial portfolio	Syndikus, Dr Isabel	Prostate	01/10/2014
TRITON 3	A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	Phase III	Commercial portfolio	Malik, Dr Zafar	Prostate	23/03/2018
TALAPRO	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib in Combination With Physician's Choice of Enzalutamide or Abiraterone Acetate/Prednisone in Patients With DNA Damage Repair Deficiencies and Metastatic Castration-Resistant Prostate	Phase III	Commercial portfolio	Syndikus, Dr Isabel	Prostate	27/10/2020
SHIRE	A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients	Phase III	Commercial portfolio	Toth, Dr Arpad (Gabe)	Haematological	05/04/2018
CHECKMATE 9DX	A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	Phase III	Commercial portfolio	Faluyi, Dr Olusola	Upper GI	28/09/2018
ARAMIS Roll-over study	An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies.	Phase III	Commercial portfolio	Syndikus, Dr Isabel		18/12/2020
BLU-285-2203	A 3 Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy	Phase II	Commercial portfolio	Butt, Dr Nauman		17/09/2021
KEYNOTE 671	A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)	Phase III	Commercial portfolio	Pope, Dr Tony	Lung	21/01/2021
IMPower	A Phase Iii, Double-Blinded, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Neoadjuvant Treatment With Atezolizumab Or Placebo In Combination With Platinum-Based Chemotherapy In Patients With Resectable Stage Ii, Iiia, Or Select Iiib Non-Small Cell Lung Cancer	Phase III	Commercial portfolio	Escriu, Dr Carlos	Lung	09/01/2020
CA045-001	A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or metastatic Melanoma	Phase III	Commercial portfolio	Chow, Dr Shien	Melanoma	06/01/2020
BraVac (Rho-Vac-002)	A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy For Localized Prostate Cancer	Phase II	Commercial portfolio	Malik, Dr Zafar	Prostate	15/06/2021
QED BGJ398	A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy	Phase II	Commercial portfolio	Palmer, Prof Daniel	Upper GI	19/12/2019
O'CARE	O'CaRE: Ovarian Cancer Retrospective European, observational study to assess burden of disease, time to next treatment and healthcare resource use in real world clinical practice.	Not Applicable	Commercial portfolio	Shaw, Dr Danielle	Gynaecological	11/11/2020
CA209-76A (EAMS)	Clinical characteristics, outcomes and quality of life in patients with squamous cell oesophageal carcinoma receiving nivolumab after prior chemotherapy as part of an early access to medicines scheme (eams) program in the united kingdom	Not Applicable	Commercial non-portfolio	Boon, Dr Cheng	Upper GI	27/08/2020
NIAGARA	A Phase III, Randomized, OPen-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for	Phase III	Commercial portfolio	Syndikus, Dr Isabel	Bladder	31/10/2019

	Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)					
OUTREACH	A First-in-Human, multi-centre, open-label, Phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH)	Phase I	Commercial portfolio	Palmer, Prof Daniel	Upper GI	06/03/2017
CARRICK CT7001	A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies	Phase I/II	Commercial portfolio	Palmieri , Prof Carlo	Breast	20/11/2019
LEAP-006	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)	Phase III	Commercial portfolio	Escriu, Dr Carlos	Lung	04/12/2019
OREO	A Phase 111b, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)	Phase III	Commercial portfolio	Lord , Dr Rosie	Gynaecological	08/06/2018
04-30 INSPIRE	A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent	Phase III	Commercial portfolio	Toth, Dr Arpad (Gabe)	Haematological	26/09/2017
FORMA 2102-HEM-101 PH2	A Phase 1/2, Multi-centre, Open-label Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome with an IDH1 Mutation.	Phase II	Commercial portfolio	Arpad, Dr Toth	Haematological	11/01/2019
HARMONY	A phase ib/ii study evaluating the safety and efficacy of obinutuzumab in combination with polatuzumab vedotin and lenalidomide in patients with relapsed or refractory follicular or diffuse large b-cell lymphoma	Phase I/II	Commercial portfolio	Arumainathan, Dr Arvind	Haematological	01/07/2017
JCAR017 Real-World Study	A non-interventional, retrospective, multi-center study to generate real-world evidence of treatment outcomes in subjects with relapsed/refractory aggressive b-cell non-hodgkin lymphoma	Not Applicable	Commercial portfolio	Kalakonda, Prof Nagesh	Haematological	19/09/2019
OCEAN	A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/ Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide	Phase III	Commercial portfolio	Brearton, Dr Gillian	Haematological	18/12/2017
PRAN-16-52	Phase Iii, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy	Phase III	Commercial portfolio	Toth, Dr Arpad (Gabe)	Haematological	16/03/2018
TRuST - Epizyme Roll-over Study	IP Rollover Study (XRuST): An Open-Label, Rollover Study		Commercial portfolio	Pettitt, Prof Andy	Haematological	08/01/2019
VEDOLIZUMAB-3035	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Phase III	Commercial portfolio	Salim, Dr Rahuman	Haematological	29/10/2019
FIRST	A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer	Phase III	Commercial portfolio	Lord , Dr Rosie	Gynaecological	23/08/2019
Ask4More: Asciminib Add-on Phase II	A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response	Phase II	Commercial portfolio	Butt, Dr Nauman	Haematological	16/04/2019
PREAMBLE	Prospective research assessment in multiple myeloma: an observational evaluation	Phase IV	Commercial portfolio	Brearton, Dr Gillian		27/10/2017
IMMUNOCORE-202	A phase ii randomized, open-label, multi-center study of the safety and efficacy of imcgp100 compared with investigator's choice in hla-a*0201 positive patients with previously untreated advanced uveal melanoma	Phase II	Commercial non-portfolio	Sacco , Dr Joseph	Melanoma	28/03/2018

BGB-290-303	A Phase 3, Double-blind, Randomised Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based First-line Chemotherapy.	Phase III	Commercial portfolio	Madi , Dr Ayman	Upper GI	30/05/2019
POLARIS 2013-001	Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma	Phase I/II	Commercial portfolio	Palmer, Prof Daniel	Upper GI	28/05/2019
EV-301	An Open-Label, Randomised Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)	Phase III	Commercial portfolio	Syndikus, Dr Isabel	Bladder	22/07/2019
TRITON 2	TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	Phase II	Commercial portfolio	Malik, Dr Zafar	Prostate	23/03/2018
CABL001A2301	A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	Phase III	Commercial portfolio	Butt, Dr Nauman	Haematological	03/08/2018
PS2	A Phase III, open-label, multicentre, randomised study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patients with treatment-naive advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy.	Phase III	Commercial portfolio	Pope, Dr Tony	Lung	05/02/2018
BEIGENE AME – BGB—290-106	A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Pamiparib following Single Oral Dose Administration in Patients with Advanced and/or Metastatic Solid Tumors	Phase I	Commercial portfolio	Palmer, Prof Daniel	Upper GI	14/03/2019
BLU-554	A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma	Phase I	Commercial portfolio	Palmer, Prof Daniel	Upper GI	13/05/2016
BAYER 17403	A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	Phase II/III	Commercial portfolio	Syndikus, Dr Isabel	Bladder	23/08/2018
KEYNOTE 629	A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)	Phase II	Commercial portfolio	Sacco , Dr Joseph	Melanoma	01/02/2018
KEYNOTE 224	A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)	Phase II	Commercial portfolio	Palmer, Prof Daniel	Upper GI	16/09/2016
SIERRA SRA737-02	A Phase I trial of oral CCT245737 (a CHK1 inhibitor) given in combination with gemcitabine plus cisplatin or gemcitabine alone in patients with advanced cancer	Phase I	Commercial portfolio	Palmer, Prof Daniel	A Select Disease Group Type	24/09/2018
IMMUNOCORE	Phase I Study of the Intra-patient Escalation Dosing Regimen	Phase I	Commercial non-portfolio	Sacco , Dr Joseph	Melanoma	27/07/2016
PFIZER B1371012 (Canc 34974)	An Open-Label Phase 1b Study Of Pf 04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Higher Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia , Or Chronic Myelomonocytic Leukemia	Phase I	Commercial portfolio	Patel, Dr Amit	Haematological	31/10/2018
AGIOS AG120-C-005	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation	Phase III	Commercial portfolio	Palmer, Prof Daniel	Upper GI	20/07/2018
TREATMENT PATTERNS OF SCLC	Treatment patterns among patients with advanced Small-Cell Lung Cancer (SCLC) in Europe	Not Applicable	Commercial portfolio	Faluyi, Dr Olusola	Lung	13/07/2018
XALT-3	Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients	Phase III	Commercial portfolio	Griffiths , Dr Richard	Lung	06/11/2017
TS102 EPOCH	EPOCH: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy	Phase III	Commercial portfolio	Montazeri, Dr Amir	Colorectal	03/09/2015

KEYNOTE 240	A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)	Phase III	Commercial portfolio	Palmer, Prof Daniel	Upper GI	22/05/2017
CA209-9TW	Retrospective chart review study of first-line treatment patterns and clinical outcomes in patients with advanced (unresectable or metastatic) melanoma in the united kingdom	Not Applicable	Commercial portfolio	Sacco , Dr Joseph	Melanoma	08/12/2017
POLO	A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy	Phase III	Commercial portfolio	Palmer, Prof Daniel	Upper GI	28/11/2014
INCB 54828-202	Study Title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy	Phase II	Commercial portfolio	Palmer, Prof Daniel	Upper GI	22/11/2017
ATLANTIS	Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial).	Phase III	Commercial portfolio	Escriu, Dr Carlos	Lung	10/10/2017
ORZORA	An open label, single arm, multicenter study to assess the clinical effectiveness and safety of Lynparza (olaparib) capsules maintenance monotherapy in platinum sensitive relapsed BRCA mutated ovarian cancer patients who are in complete or partial response following platinum based chemotherapy (ORZORA)	Phase IV	Commercial portfolio	Lord , Dr Rosie	Gynaecological	21/10/2016
CYP-001 for the Treatment of Acute Graft vs Host Disease	An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease	Phase I/II	Commercial portfolio	Salim, Dr Rahuman	Haematological	23/10/2017
PISARRO	PiSARRO - p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	Phase I/II	Commercial portfolio	Green, Dr John	Gynaecological	15/09/2017
9785-CL-0123	A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study	Phase II	Commercial portfolio	Malik, Dr Zafar	Prostate	06/11/2017
ANNOUNCE-2	A Phase 1b (Open Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating the Efficacy of Gemcitabine and Docetaxel With or Without a Human Anti-PDGFRa Monoclonal Antibody (Olaratumab) in the Treatment of Advanced Soft Tissue Sarcoma	Phase Ib/II	Commercial portfolio	Ali, Dr Nasim	Sarcoma	23/08/2017
CHECKMATE 714	A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (CheckMate 714)	Phase II	Commercial portfolio	Sacco , Dr Joseph	Head & Neck	04/04/2017
RELAY	A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer	Phase III	Commercial portfolio	Escriu, Dr Carlos	Lung	18/05/2017
JAVELIN OVARIAN 100	A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of avelumab (msb0010718c) in combination with and/or following chemotherapy in patients with previously untreated epithelial ovarian cancer	Phase III	Commercial portfolio	Lord , Dr Rosie	Gynaecological	07/03/2017
ABI-007-NSCL-006	A Phase 2, randomized, open-label, multicenter study to assess safety and efficacy of nabpaclitaxel (Abraxane) with epigenetic modifying therapy of CC-486, and nabpaclitaxel monotherapy as second-line treatment in subjects with advanced nonsquamous non-small cell lung cancer (NSCLC): ABOUND.2L	Phase II	Commercial portfolio	Escriu, Dr Carlos	Lung	27/04/2016
MO29518	An Open-Label, Multicohort, Phase II Study Of Mpd13280a In Advanced Solid Tumours	Phase II	Commercial portfolio	Palmer, Prof Daniel	A Select Disease Group Type	02/12/2015
CHECKMATE 817	Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies	Phase III/IV	Commercial portfolio	Escriu, Dr Carlos	Lung	01/07/2017
PASTOR	A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a background of Hormonal Therapy in Patients with Locally Advanced/Metastatic	Phase I	Commercial portfolio	Palmieri , Prof Carlo	Breast	28/06/2017

	Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension					
JAVELIN GASTRIC	A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction	Phase III	Commercial portfolio	Madi , Dr Ayman	Upper GI	25/01/2017
LDK378 Food Affect Study	A Phase I, multi-center, randomized open label study to assess the systemic exposure and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)	Phase I	Commercial portfolio	Escriu, Dr Carlos	Lung	02/02/2016
CELESTIAL	A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who have Received Prior Sorafenib	Phase III	Commercial portfolio	Palmer, Prof Daniel	Upper GI	28/04/2014
CHECKMATE 451	A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy	Phase III	Commercial portfolio	Pope, Dr Tony	Lung	31/05/2016
TS103 STOP HCC	A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC)	Phase III	Commercial portfolio	Palmer, Prof Daniel		23/06/2016
JAVELIN LUNG	A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non-small-cell lung cancer	Phase III	Commercial portfolio	Escriu, Dr Carlos	Lung	22/08/2016
JSBF (I3O-MC-JSBF)	Protocol I3O-MC-JSBF Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestininb or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer	Phase II	Commercial portfolio	Palmer, Prof Daniel	Upper GI	25/04/2017
Medimmune MII41910-419010	A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4Antibody) in Subjects with Advanced Solid Tumors	Phase I	Commercial portfolio	Syndikus, Dr Isabel	A Select Disease Group Type	01/11/2016
ALLIGATOR	Alligator - ADC-1013 First-in-Human study	Phase I	Commercial non-portfolio	Palmer, Prof Daniel	Upper GI	30/11/2015
JAVELIN OVARIAN 200	A Phase III, open label, randomized study of avelumab given as single agent, or in combination with pegylated liposomal doxorubicin, compared to pegylated liposomal doxorubicin alone in platinum resistant/ refractory ovarian cancer	Phase III	Commercial portfolio	Lord , Dr Rosie	Gynaecological	03/11/2016
JANSSEN BLADDER	A Phase II, 2-Arm MultiCenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations	Phase II	Commercial portfolio	Syndikus, Dr Isabel	Bladder	22/10/2015
JANSSEN PROSTATE	A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)	Phase III	Commercial portfolio	Syndikus, Dr Isabel	Prostate	20/07/2015
RANGE	RANGE - Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy	Phase III	Commercial portfolio	Syndikus, Dr Isabel	Bladder	06/10/2015
KESTREL	A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients (KESTREL)	Phase III	Commercial portfolio	Sacco , Dr Joseph	Head & Neck	24/02/2016
CHECKMATE 459	A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma	Phase III	Commercial portfolio	Palmer, Prof Daniel	Upper GI	13/07/2016
REASSURE	REASSURE Radium223 alpha emitter agent in safety study in mCRPC population for longterm evaluation	Phase IV	Commercial portfolio	Syndikus, Dr Isabel	Prostate	27/04/2015

GTx 802	A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women	Phase II	Commercial portfolio	Palmieri , Prof Carlo	Breast	19/08/2016
BI 1208.8 PROSTATE STUDY	A Phase Ib/II, Multicentre, Open Label, Randomised Study of BI 836845 in Combination with Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone	Phase Ib/II	Commercial portfolio	Syndikus, Dr Isabel	Prostate	18/11/2014
WO29637	A phase III, open-label, randomized study of MPDL3280A (Anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma	Phase III	Commercial portfolio	Griffiths , Dr Richard	Renal	09/10/2015
MK-3475-054	Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group	Phase III	Commercial portfolio	Sacco , Dr Joseph	Melanoma	18/03/2016
Bayer 15396 (Radium 23)	A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)	Phase III	Commercial portfolio	Syndikus, Dr Isabel	Prostate	24/06/2014
RAINFALL	NCRN3464 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)	Phase III	Commercial portfolio	Madi , Dr Ayman	Upper GI	23/10/2015
CA209040-CHECKMATE 040	A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis	Phase I	Commercial portfolio	Palmer, Prof Daniel	Upper GI	24/03/2015
SPARTAN ARAGON	SPARTAN - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer	Phase III	Commercial portfolio	Malik, Dr Zafar	Prostate	25/04/2014
MK3475	A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer	Phase II	Commercial portfolio	Syndikus, Dr Isabel	Bladder	17/08/2015
TVEC 325	A Phase 2 Open-label, Multicenter, Single arm Trial to Evaluate the Immunoprofile of Subjects With Unresected Stage IIIB - IVM1a Melanoma Treated with Talimogene Laherparepvec	Phase II	Commercial portfolio	Sacco , Dr Joseph	Melanoma	16/07/2015
Announce	ANNOUNCE - A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma	Phase III	Commercial portfolio	Ali, Dr Nasim	Sarcoma	11/03/2016
ARAMIS	A multinational, randomised, double-blind, placebo-controlled, phase iii efficacy and safety study of odm-201 in men with high-risk non-metastatic castration-resistant prostate cancer	Phase III	Commercial portfolio	Syndikus, Dr Isabel	Prostate	30/01/2015
COLUMBUS	NCRN 567 - A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma	Phase III	Commercial portfolio	Marshall, Dr Ernie	Melanoma	09/07/2014
PRESIDE	A Randomized, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients treated with Docetaxel plus Prednisolone who have Progressed on Enzalutamide Alone	Phase III	Commercial portfolio	Malik, Dr Zafar	Prostate	03/02/2015
EISAI E7080-304	A Multicenter, Randomized, OpenLabel, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in FirstLine Treatment of Subjects With Unresectable Hepatocellular Carcinoma	Phase III	Commercial portfolio	Palmer, Prof Daniel	Upper GI	21/08/2014
CHECKMATE 141	CHECKMATE 141: An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator'sChoice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Phase III	Commercial portfolio	Husband, Dr David	Head & Neck	19/08/2014

CHECKMATE 143	A Randomised Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)	Phase II	Commercial portfolio	MEHTA, Dr Shaveta	Head & Neck	20/10/2014
NEMO	NCRN492 - The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing the efficacy of MEK162 versus Dacarbazine in patients with advanced unresectable or metastatic NRAS mutation positive melanoma	Phase III	Commercial portfolio	Marshall, Dr Ernie	Melanoma	21/11/2013
OBLIQUE	A Phase IV Observational study to assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors receiving treatment with oral 10mg Everlimus (Afinitor®) o.d.: The OBLIQUE Study (CRAD001PGB12)	Phase IV	Commercial portfolio	Faluyi, Dr Olusola	Upper GI	09/04/2014
IMAGE	A Multi-National, Prospective, Observational Study in Patients with Unresectable or Metastatic Melanoma	Phase IV	Commercial portfolio	Marshall, Dr Ernie	Melanoma	12/07/2013
POLARIS	A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy	Phase III	Commercial portfolio	Palmer, Prof Daniel	Upper GI	14/05/2013
DETERMINE MESOTHELIOMA	Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma	Phase II	Commercial portfolio	Griffiths , Dr Richard	Renal	09/12/2013
AFFINITY OGX-11-12	A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer	Phase III	Commercial portfolio	Malik, Dr Zafar	Prostate	18/01/2013
SAFEHER	SafeHer: Safety study with subcutaneous Trastuzumab in breast cancer	Phase III	Commercial non-portfolio	Malik, Dr Zafar	Breast	24/01/2013
APHINITY	A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer	Phase III	Commercial portfolio	Palmieri , Prof Carlo		09/02/2012